Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing

Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin

doi:10.3389/fonc.2021.706798

Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing

Front Oncol. 2021 Jul 8:11:706798. doi: 10.3389/fonc.2021.706798. eCollection 2021.

Authors

Huan-Ping Wang^{1

2}, Jun-Jun He³, Qiao-Yun Zhu⁴, Lin Wang³, Jian-Hu Li¹, Jian-Song Huang^{1

2}, Wan-Zhuo Xie¹, Hong-Hu Zhu^{1

2}, Jie Jin^{1

2}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, China.
³ Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
⁴ Central Laboratory, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Abstract

The NUP214-ABL1 fusion gene is a constitutively active tyrosine kinase that can be detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL) patients, and it can also be found in B-cell acute lymphoblastic leukaemia (B-ALL). However the NUP214-ABL1 fusion in acute myeloid leukemia (AML) has not yet been reported. Up to now, the sensitivity of NUP214-ABL1-positive patients to tyrosine kinase inhibitor (TKI) is still controversial. Here we report the first case of an AML patient carrying NUP214-ABL1 fusion gene. The conventional AML chemotherapy regimen for the patient was successful. Identification of additional AML patients with NUP214-ABL1 fusion gene will provide treatment experience and prognostic evaluation.

Keywords: ABL1; NUP214-ABL1; acute myeloid leukemia; next-generation sequencing; tyrosine kinase.

Publication types

Case Reports